These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 36172901)
21. An Inpatient Psychiatric Program Targeting Opioid Overdoses. Mahgoub N; O'Connell K; Gevint K; Dedonatis A; Velasco J; Tham A; Cangemi S; Tai FJ; Stellman M; Radosta M; Anthony D J Psychiatr Pract; 2020 Jan; 26(1):71-75. PubMed ID: 31913974 [TBL] [Abstract][Full Text] [Related]
22. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders. Abdelal R; Raja Banerjee A; Carlberg-Racich S; Darwaza N; Ito D; Shoaff J; Epstein J Harm Reduct J; 2022 May; 19(1):49. PubMed ID: 35596213 [TBL] [Abstract][Full Text] [Related]
23. Rates and Costs of Dispensing Naloxone to Patients at High Risk for Opioid Overdose in the United States, 2014-2018. Barenie RE; Gagne JJ; Kesselheim AS; Pawar A; Tong A; Luo J; Bateman BT Drug Saf; 2020 Jul; 43(7):669-675. PubMed ID: 32180134 [TBL] [Abstract][Full Text] [Related]
24. Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island. Zang X; Macmadu A; Krieger MS; Behrends CN; Green TC; Morgan JR; Murphy SM; Nolen S; Walley AY; Schackman BR; Marshall BD Int J Drug Policy; 2021 Dec; 98():103435. PubMed ID: 34482264 [TBL] [Abstract][Full Text] [Related]
25. Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020. Cremer LJ; Board A; Guy GP; Schieber L; Asher A; Parker EM Drug Alcohol Depend; 2022 Mar; 232():109192. PubMed ID: 35065513 [TBL] [Abstract][Full Text] [Related]
26. Opioid Overdose Harm Prevention: The Role of the Nurse in Patient Education. Gilles S Nurs Clin North Am; 2022 Sep; 57(3):477-488. PubMed ID: 35985734 [TBL] [Abstract][Full Text] [Related]
27. Lessons learned from ramping up a Canadian Take Home Naloxone programme during a public health emergency: a mixed-methods study. Young S; Williams S; Otterstatter M; Lee J; Buxton J BMJ Open; 2019 Oct; 9(10):e030046. PubMed ID: 31662368 [TBL] [Abstract][Full Text] [Related]
28. The Rhode Island community responds to opioid overdose deaths. Bowman S; Engelman A; Koziol J; Mahoney L; Maxwell C; McKenzie M R I Med J (2013); 2014 Oct; 97(10):34-7. PubMed ID: 25271658 [TBL] [Abstract][Full Text] [Related]
29. Willingness to use a wearable device capable of detecting and reversing overdose among people who use opioids in Philadelphia. Kanter K; Gallagher R; Eweje F; Lee A; Gordon D; Landy S; Gasior J; Soto-Calderon H; Cronholm PF; Cocchiaro B; Weimer J; Roth A; Lankenau S; Brenner J Harm Reduct J; 2021 Jul; 18(1):75. PubMed ID: 34301246 [TBL] [Abstract][Full Text] [Related]
30. Disparities in opioid overdose survival and naloxone administration in Pennsylvania. Holmes LM; Rishworth A; King BH Drug Alcohol Depend; 2022 Sep; 238():109555. PubMed ID: 35810621 [TBL] [Abstract][Full Text] [Related]
31. Local health departments and the implementation of evidence-based policies to address opioid overdose mortality. Feuerstein-Simon R; Lowenstein M; Sharma M; Dupuis R; Luna Marti X; Cannuscio CC Subst Abus; 2020; 41(4):468-474. PubMed ID: 32213045 [TBL] [Abstract][Full Text] [Related]
32. Attitude changes following short-form opioid overdose video education: a pilot study. Galiher MV; Huffman M Harm Reduct J; 2022 Oct; 19(1):114. PubMed ID: 36241995 [TBL] [Abstract][Full Text] [Related]
33. Distribution of intranasal naloxone to potential opioid overdose bystanders in Sweden: effects on overdose mortality in a full region-wide study. Håkansson A; Alanko Blomé M; Isendahl P; Landgren M; Malmqvist U; Troberg K BMJ Open; 2024 Jan; 14(1):e074152. PubMed ID: 38171623 [TBL] [Abstract][Full Text] [Related]
34. Expanded access to naloxone: options for critical response to the epidemic of opioid overdose mortality. Kim D; Irwin KS; Khoshnood K Am J Public Health; 2009 Mar; 99(3):402-7. PubMed ID: 19150908 [TBL] [Abstract][Full Text] [Related]
35. Indian Health Service pharmacists engaged in opioid safety initiatives and expanding access to naloxone. Duvivier H; Gustafson S; Greutman M; Jangchup T; Harden AK; Reinhard A; Warshany K J Am Pharm Assoc (2003); 2017; 57(2S):S135-S140. PubMed ID: 28292501 [TBL] [Abstract][Full Text] [Related]
36. Concerns that an opioid antidote could "make things worse": Profiles of risk compensation beliefs using the Naloxone-Related Risk Compensation Beliefs (NaRRC-B) scale. Winograd RP; Werner KB; Green L; Phillips S; Armbruster J; Paul R Subst Abus; 2020; 41(2):245-251. PubMed ID: 31170030 [No Abstract] [Full Text] [Related]
37. Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US. Ballreich J; Mansour O; Hu E; Chingcuanco F; Pollack HA; Dowdy DW; Alexander GC JAMA Netw Open; 2020 Nov; 3(11):e2023677. PubMed ID: 33146732 [TBL] [Abstract][Full Text] [Related]
38. The opioid crisis: Origins, trends, policies, and the roles of pharmacists. Chisholm-Burns MA; Spivey CA; Sherwin E; Wheeler J; Hohmeier K Am J Health Syst Pharm; 2019 Mar; 76(7):424-435. PubMed ID: 31361827 [TBL] [Abstract][Full Text] [Related]
39. Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Davis CS; Carr D Drug Alcohol Depend; 2015 Dec; 157():112-20. PubMed ID: 26507172 [TBL] [Abstract][Full Text] [Related]
40. Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States. Smart R; Pardo B; Davis CS Addiction; 2021 Jan; 116(1):6-17. PubMed ID: 32533570 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]